Valuation: Inovio Pharmaceuticals, Inc.

Market Cap 62.29M 55.78M 51.31M 46.49M 86.91M 5.91B 88.53M 612M 246M 3.11B 234M 229M 9.81B P/E 2026 *
-0.75x
P/E 2027 * -1.38x
Enterprise Value 62.29M 55.78M 51.31M 46.49M 86.91M 5.91B 88.53M 612M 246M 3.11B 234M 229M 9.81B EV / Sales 2026 *
93.4x
EV / Sales 2027 * 1.23x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day-21.95%
1 week-32.85%
1 month-50.62%
3 months-11.02%
6 months-46.21%
Current year-65.38%
1 week 0.6
Extreme 0.5961
0.98
1 month 0.6
Extreme 0.5961
1.23
Current year 0.56
Extreme 0.5632
2.03
1 year 0.56
Extreme 0.5632
2.72
3 years 0.56
Extreme 0.5632
14.75
5 years 0.56
Extreme 0.5632
93.24
10 years 0.56
Extreme 0.5632
405.48
Manager TitleAgeSince
Chief Executive Officer 60 10/05/2022
Director of Finance/CFO 62 01/06/2002
Chief Tech/Sci/R&D Officer 60 27/06/2022
Director TitleAgeSince
Chairman 81 03/01/2019
Director/Board Member 69 11/03/2016
Director/Board Member 71 06/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/26 Free

Director

76,000 0.0928%
20/05/26 Exercice

Chief Technology Officer

75,817 0.0925%
20/05/26 Free

Chairman

76,000 0.0928%
Change 5-day change 1-year change 3-year change Capi.($)
-21.95%-32.85%-74.37%-86.22% 62.29M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -1.89%+3.50%+35.38%+166.87% 39.44B
Weighted average by Cap. +0.17%+5.44%+47.97%+176.63%

Financials

2026 *2027 *
Net sales 667K 597K 549K 498K 930K 63.3M 948K 6.55M 2.63M 33.3M 2.5M 2.45M 105M 50.61M 45.32M 41.69M 37.77M 70.61M 4.81B 71.93M 497M 200M 2.53B 190M 186M 7.97B
Net income -68.03M -60.93M -56.04M -50.78M -94.92M -6.46B -96.7M -668M -268M -3.4B -255M -250M -10.72B -56.49M -50.59M -46.53M -42.16M -78.81M -5.36B -80.29M -555M -223M -2.82B -212M -207M -8.9B
Net Debt - -
Projected Income Statement - Annual - Inovio Pharmaceuticals, Inc.
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Employees
112
Date Price Change Volume
30/10/26 $0.6024 -21.95% 80,501,396
29/10/26 $0.7718 -16.89% 9,642,419
28/10/26 $0.9286 +4.34% 4,569,019
27/10/26 $0.8900 +2.32% 3,798,877
26/10/26 $0.8698 -3.04% 2,965,853
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Inovio Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.6024USD
Average target price
3.167USD
Spread / Average Target
+425.68%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Inovio Pharmaceuticals, Inc.